[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606192":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":39,"locations":45,"responsibleParty":62,"collaborators":11,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Jiangsu vcare pharmaceutical technology co., LTD","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"VC005 Tablets Low Dose groups","EXPERIMENTAL",null,[13],"Drug: VC005 tablets",{"label":15,"type":10,"description":11,"interventionNames":16},"VC005 Tablets High Dose groups",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"VC005 Tablets Placebo groups","PLACEBO_COMPARATOR",[21],"Drug: VC005 Tablets Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","VC005 tablets","VC005 groups repeat administration for 48 weeks",[15,9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"VC005 Tablets Placebo","VC005 placebo groups repeat administration for 48 weeks",[18],[33,37],{"name":34,"affiliation":35,"role":36},"Zhanguo Li","Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",{"name":38,"affiliation":35,"role":36},"Xu Liu",[40],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"xiaojuan lai","CONTACT","15358160458","lai_xiaojuan@vcarepharmatech.com",[46],{"facility":35,"status":47,"city":48,"state":49,"zip":11,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":53,"coordinates":54},"Point",[55,56],116.39723,39.9075,{"lat":56,"lon":55},[59],{"name":34,"role":42,"phone":60,"phoneExt":11,"email":61},"13910713924","Zgli99@aliyun.com",{"type":63,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606192","phase-3-efficacy-and-safety-phase-iii-clinical-study-of-vc005-tablets-in-subjects-with-active-ankylosing-spondylitis-100606192",false,"NCT07172360","Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.","A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;\n* The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;\n* The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis\n\nExclusion Criteria:\n\n* Those who may be allergic to VC005, similar drugs or their excipients.\n* Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.\n* Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.","ALL","18 Years","70 Years",{"count":75,"type":76},420,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.",[82],"Active Ankylosing Spondylitis","2025-12-29",{"date":85,"type":86},"2026-01-02","ACTUAL",{"date":88,"type":86},"2025-12-26",{"date":90,"type":76},"2027-08-30",{"name":5,"class":6},1]